AR071910A1 - Vacuna combinada para el papiloma humano y el sarampion. vector. huesped. - Google Patents
Vacuna combinada para el papiloma humano y el sarampion. vector. huesped.Info
- Publication number
- AR071910A1 AR071910A1 ARP090101881A ARP090101881A AR071910A1 AR 071910 A1 AR071910 A1 AR 071910A1 AR P090101881 A ARP090101881 A AR P090101881A AR P090101881 A ARP090101881 A AR P090101881A AR 071910 A1 AR071910 A1 AR 071910A1
- Authority
- AR
- Argentina
- Prior art keywords
- hpv
- vaccine
- measles
- recombinant
- hpv6
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Vacunas combinadas contra el sarampion y el virus del papiloma humano (HPV). Vectores del virus de sarampion recombinantes que contienen cido nucleico heterologo que codifica uno o varios ant¡genos derivados del HPV, preferentemente, el ant¡geno L1 de la c pside mayor, el ant¡geno L2 de la c pside menor, oncoprote¡nas del gen temprano E6 y gen temprano E7 del HPV tipo 16, y opcionalmente de los tipos 18, 6 y 11. En una primera realizacion, las vacunas profil cticas se generan expresando ant¡genos HPV, preferentemente L1 y/o L2. En otra realizacion, las vacunas terapeuticas se generan expresando prote¡nas E6 y E7, y opcionalmente L1 y L2. Reivindicacion 1: Una vacuna para el sarampion y el HPV combinada caracterizada porque comprende los virus de la vacuna para el sarampion recombinados que expresan ant¡genos HPV capaces de sacar una respuesta inmunologica y proporcionar proteccion contra el sarampion y el HPV, Reivindicacion 11: Un vector caracterizado porque comprende la secuencia de nucleotidos de ant¡genos de diferentes tipos de HPV y sarampion. Reivindicacion 14: El vector tal como se reivindica en la reivindicacion 11, caracterizado porque el ant¡geno se selecciona de prote¡nas L1 o L2 o E6 o E7 de HPV-16, HPV-18, HPV-6 y HPV-11. Reivindicacion 23: La vacuna tal como se reivindica en cualquiera de las reivindicaciones precedentes caracterizada porque comprende el virus del sarampion recombinante que tiene insertada una secuencia de cido nucleico que codifica el HPV16-L1 o HPV18-L1 o HPV6-L1 o HPV11-L1 o HPV16-L2 o HPV18-L2 o HPV6-L2 o HPV11-L2 o HPV1I6-E6 o HPV18-E6 o HPV6-E6 o HPV16-E7 o HPV18-E7 o HPV6-E7 o cualquiera de sus combinaciones. Reivindicacion 27: Una vacuna tal corno se reivindica en la reivindicacion 25, caracterizada porque el adyuvante es una interleuquina, preferentemente interleuquina 2. Reivindicacion 28 :Una vacuna tal como se reivindica en cualquiera de las reivindicaciones precedentes, caracterizada porque la vacuna consiste esencialmente de al menos uno de los virus del HPV y el sarampion recombinantes o una mezcla de dos o varios de tales virus. Reivindicacion 34: Una vacuna tal corno se reivindica en las reivindicaciones precedentes es un componente de una vacuna combinada caracterizada porque los otros componentes son virus de rubeola, paperas, varicela u otro virus de vacuna atenuada viva, atenuada naturalmente o recombinante, solos o combinados.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1113MU2008 | 2008-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071910A1 true AR071910A1 (es) | 2010-07-21 |
Family
ID=42316922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101881A AR071910A1 (es) | 2008-05-26 | 2009-05-26 | Vacuna combinada para el papiloma humano y el sarampion. vector. huesped. |
Country Status (13)
Country | Link |
---|---|
US (1) | US9623098B2 (es) |
EP (1) | EP2280728B1 (es) |
JP (1) | JP5726727B2 (es) |
CN (2) | CN102099053A (es) |
AR (1) | AR071910A1 (es) |
AU (1) | AU2009336562B2 (es) |
BR (1) | BRPI0909547A2 (es) |
CA (1) | CA2722847C (es) |
EA (1) | EA027784B1 (es) |
ES (1) | ES2565846T3 (es) |
TW (1) | TWI561244B (es) |
WO (1) | WO2010079505A2 (es) |
ZA (1) | ZA201007595B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001075277A1 (en) | 2000-03-31 | 2001-10-11 | Northern Research And Engineering Corporation | Solid-fueled power generation system with carbon dioxide sequestration and method therefor |
EP1375670B1 (en) * | 2002-06-20 | 2013-06-12 | Institut Pasteur | Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions |
ES2330309T3 (es) | 2002-06-20 | 2009-12-09 | Institut Pasteur | Adnc infeccioso de una cepa de vacuna aprobada de virus del sarampion. uso para composiciones inmunogenicas. |
CA2432738A1 (en) | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
SG10201402048UA (en) * | 2009-05-05 | 2014-08-28 | Cadila Healthcare Ltd | Combined measles-malaria vaccine |
CA2848658C (en) * | 2011-10-12 | 2022-08-02 | The Trustees Of The University Of Pennsylvania | Vaccines for human papilloma virus and methods for using the same |
WO2013074501A1 (en) * | 2011-11-14 | 2013-05-23 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
KR20150130438A (ko) | 2013-03-12 | 2015-11-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 인간 파밀로마 바이러스용 개선된 백신 및 이것을 사용하는 방법 |
CN105801704B (zh) * | 2014-12-31 | 2020-06-02 | 艾托金生物医药(苏州)有限公司 | 一种具有抗***细胞活性的重组疫苗构建方法及应用 |
CN104830869B (zh) * | 2015-04-30 | 2018-06-01 | 武汉凯德维斯生物技术有限公司 | 与***发生相关的hpv整合的基因位点及其应用 |
KR20180057610A (ko) | 2015-08-03 | 2018-05-30 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 브라큐리 결실 돌연변이체, 브라큐리 결실 돌연변이체를 인코딩하는 비-효모 벡터, 및 이들의 용도 |
RU2681174C1 (ru) * | 2018-07-12 | 2019-03-04 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9113809D0 (en) | 1991-06-26 | 1991-08-14 | Cancer Res Campaign Tech | Papillomavirus l2 protein |
DE122007000023I1 (de) | 1991-07-19 | 2007-08-09 | Univ Queensland St Lucia | Impfsstoff gegen Humanes Papillomavirus (typ 18) |
DE122007000096I1 (de) | 1992-06-25 | 2008-03-27 | Papillomavirus vakzine | |
US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
DE122007000090I1 (de) | 1993-03-09 | 2008-03-27 | Univ Rochester | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
DK0780475T4 (da) | 1995-08-09 | 2006-10-23 | Schweiz Serum & Impfinst | Fremgangsmåde til fremstilling af infektiöse negativ-streng RNA-virus |
CA2324289C (en) * | 1998-03-09 | 2010-07-13 | Smithkline Beecham Biologicals S.A. | Combined vaccine compositions |
CZ301212B6 (cs) * | 1998-10-16 | 2009-12-09 | Smithkline Beecham Biologicals S. A. | Vakcinacní prostredek |
GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
EP1375670B1 (en) * | 2002-06-20 | 2013-06-12 | Institut Pasteur | Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions |
AU2003295502A1 (en) | 2002-11-12 | 2004-06-03 | Yucheng Chang | Adenoviral vector vaccine |
CA2432738A1 (en) | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
MY139500A (en) * | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
WO2007120120A2 (en) * | 2005-01-12 | 2007-10-25 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Attenuated human parainfluenza virus, methods and uses thereof |
-
2009
- 2009-05-26 TW TW098117618A patent/TWI561244B/zh not_active IP Right Cessation
- 2009-05-26 CA CA2722847A patent/CA2722847C/en not_active Expired - Fee Related
- 2009-05-26 AU AU2009336562A patent/AU2009336562B2/en not_active Ceased
- 2009-05-26 BR BRPI0909547-0A patent/BRPI0909547A2/pt not_active Application Discontinuation
- 2009-05-26 JP JP2011511167A patent/JP5726727B2/ja active Active
- 2009-05-26 EP EP09828417.7A patent/EP2280728B1/en active Active
- 2009-05-26 CN CN2009801194069A patent/CN102099053A/zh active Pending
- 2009-05-26 EA EA201071366A patent/EA027784B1/ru not_active IP Right Cessation
- 2009-05-26 CN CN201610737988.9A patent/CN106377767A/zh active Pending
- 2009-05-26 WO PCT/IN2009/000302 patent/WO2010079505A2/en active Application Filing
- 2009-05-26 US US12/993,693 patent/US9623098B2/en not_active Expired - Fee Related
- 2009-05-26 AR ARP090101881A patent/AR071910A1/es unknown
- 2009-05-26 ES ES09828417.7T patent/ES2565846T3/es active Active
-
2010
- 2010-10-25 ZA ZA2010/07595A patent/ZA201007595B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2722847A1 (en) | 2010-07-15 |
EA027784B1 (ru) | 2017-09-29 |
AU2009336562A1 (en) | 2010-07-15 |
CA2722847C (en) | 2019-12-17 |
CN106377767A (zh) | 2017-02-08 |
ZA201007595B (en) | 2011-09-28 |
WO2010079505A2 (en) | 2010-07-15 |
TW201010718A (en) | 2010-03-16 |
AU2009336562B2 (en) | 2012-12-20 |
ES2565846T3 (es) | 2016-04-07 |
TWI561244B (en) | 2016-12-11 |
EP2280728B1 (en) | 2016-03-02 |
EA201071366A1 (ru) | 2011-06-30 |
BRPI0909547A2 (pt) | 2019-03-06 |
US9623098B2 (en) | 2017-04-18 |
JP2011524863A (ja) | 2011-09-08 |
JP5726727B2 (ja) | 2015-06-03 |
US20110129493A1 (en) | 2011-06-02 |
CN102099053A (zh) | 2011-06-15 |
EP2280728A2 (en) | 2011-02-09 |
WO2010079505A3 (en) | 2010-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR071910A1 (es) | Vacuna combinada para el papiloma humano y el sarampion. vector. huesped. | |
CY1124618T1 (el) | Ανασυνδυασμενοι hvt φορεις οι οποιοι εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων | |
EA201391109A1 (ru) | Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования | |
EA201201025A1 (ru) | Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них | |
CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
EA201492110A1 (ru) | Вакцины против впг-2 | |
MX344069B (es) | Vacuna vectorizada por el herpesvirus de los pavos contra la influenza aviar en aves de corral. | |
MX354750B (es) | PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA. | |
MX358762B (es) | Procesos que utilizan vlps con cápsides resistentes a hidrolasas. | |
EP3156070A3 (en) | Newcastle disease virus vectored herpesvirus vaccines | |
EA201691120A1 (ru) | Векторные композиции и способы индукции усиленного иммунного ответа с использованием векторов поксвируса | |
CO6670515A2 (es) | Vectores de parapoxvirus | |
WO2011057254A3 (en) | Simian adenoviral vector-based vaccines | |
CO6541529A2 (es) | Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos | |
UY33523A (es) | ?vectores de parapoxvirus?. | |
PH12017501100A1 (en) | Recombinant swinepox virus and vaccines | |
AR109540A1 (es) | Moléculas promotoras para expresar antígenos virales | |
AR066823A1 (es) | Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp | |
PH12020500526A1 (en) | Paramyxoviridae expression system | |
MX2017014417A (es) | Vacunas contra el dengue. | |
EA201992602A2 (ru) | Вакцины против впг-2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |